Companies › Beijing Biostar Pharmaceuticals
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Utidelone Capsule (UTD2) Microtubule stabilizer; tubulin inhibitor | Tubulin | Phase 2 | Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid Tumor | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05700084 | Utidelone Capsule (UTD2) | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT05700084 | Utidelone Capsule (UTD2) | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT06841679 | Utidelone Capsule (UTD2) | Phase 2 | Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Sep 2030 |
Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen Fidia Farmaceutici GSK Urotronic Ambrx
Fidia Farmaceutici Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.